Seattle Genetics to Present at JMP Securities Healthcare Focus Conference

Strategic Insights -

Seattle Genetics, a clinical stage biotechnology company focused on cancer and autoimmune disease therapies, announced that its management team will present at the Fourth Annual JMP Securities Healthcare Focus Conference on October 5, 2009. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA. Seattle Genetics has collaborations with several leading biotechnology and pharmaceutical companies, including Genentech, Bayer, and Millennium: The Takeda Oncology Company, to develop its ADC technology.

Key Takeaways:

  • Seattle Genetics will present at the Fourth Annual JMP Securities Healthcare Focus Conference on October 5, 2009.
  • The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA.
  • Seattle Genetics has a collaboration with Genentech to develop dacetuzumab (SGN-40).
  • The company has collaborations with several other biotechnology and pharmaceutical companies, including Bayer and Millennium: The Takeda Oncology Company, to develop its ADC technology.
  • Seattle Genetics has three product candidates in ongoing late-stage clinical trials, including lintuzumab (SGN-33) and brentuximab vedotin (SGN-35).
  • The company has one product candidate, SGN-70, in early-stage clinical trials.

Statistics:

  • October 5, 2009: date of Seattle Genetics' presentation at the Fourth Annual JMP Securities Healthcare Focus Conference.
  • 8:30 a.m. Eastern Time: time of Seattle Genetics' presentation at the conference.
  • 2009: year in which Seattle Genetics announced its management team's presentation at the conference.
  • SGN-35: number of brentuximab vedotin (SGN-35) product candidates.
  • SGN-33: number of lintuzumab (SGN-33) product candidates.
  • SGN-40: number of dacetuzumab (SGN-40) product candidates.

Sources:

  • Seattle Genetics, Inc. News Release, October 2009.
  • Seattle Genetics, Inc. Website, www.seattlegenetics.com.
  • JMP Securities Healthcare Focus Conference Program.